Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Bluejay Diagnostics reported Q2 2026 results highlighting the completion of targeted enrollment in its SYMON-II pivotal clinical study for the Symphony IL-6 test, advancement toward FDA 510(k) submission, and a strengthened balance sheet with $9.6 million in cash following a significant private placement financing. The company also signed a US manu…